Jane Street Group, LLC Scynexis Inc Transaction History

Jane Street Group, LLC

$444 Billion
Q4 2024

A detailed history of Jane Street Group, LLC transactions in Scynexis Inc stock. As of the latest transaction made, Jane Street Group, LLC holds 26,507 shares of SCYX stock, worth $29,422. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,507

Holding current value

$29,422

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.0 - $1.53 $26,507 - $40,555	26,507 New	26,507 $30,000
Q2 2024 Aug 14, 2024	SELL	$1.4 - $2.77 $102,419 - $202,644	-73,157 Reduced 78.06%	20,562 $41,000
Q1 2024 May 15, 2024	BUY	$1.39 - $2.21 $130,269 - $207,118	93,719 New	93,719 $137,000
Q2 2023 Aug 14, 2023	SELL	$2.38 - $3.67 $5,366 - $8,275	-2,255 Reduced 16.85%	11,131 $32,000
Q1 2023 May 15, 2023	BUY	$1.15 - $3.0 $15,393 - $40,158	13,386 New	13,386 $40,000
Q3 2022 Nov 14, 2022	SELL	$1.83 - $2.93 $1,601 - $2,563	-875 Reduced 3.4%	24,870 $60,000
Q2 2022 Aug 16, 2022	BUY	$1.77 - $3.87 $45,568 - $99,633	25,745 New	25,745 $48,000
Q1 2021 May 18, 2021	SELL	$6.93 - $9.63 $69,868 - $97,089	-10,082 Closed	0 $0
Q4 2020 Feb 17, 2021	BUY	$4.28 - $7.87 $43,150 - $79,345	10,082 New	10,082 $77,000

Others Institutions Holding SCYX

# of Institutions

Shares Held

12.7M

Call Options Held

Put Options Held

Federated Hermes, Inc. Pittsburgh, PA

2.9M
Shares

$3.21 Million
0.01% of portfolio
Kingdon Capital Management, L.L.C. New York, NY

2.24M
Shares

$2.48 Million
0.42% of portfolio
Vanguard Group Inc Valley Forge, PA

1.66M
Shares

$1.84 Million
0.0% of portfolio
Avidity Partners Management LP Dallas, TX

1.23M
Shares

$1.36 Million
0.16% of portfolio
Amh Equity LTD

626K
Shares

$694,917
0.79% of portfolio

View Full List

About SCYNEXIS INC

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $36.2M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

More about SCYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Account